CD19 and antisynthetase syndrome: Similarly, a 41-year-old man with the refractory antisynthetase syndrome (ASyS) experienced minimal adverse events after receiving CD19-CAR T cell therapy, despite the significant expansion of CD19-CAR T cells in vivo (89).